低危轻度高血压患者降压治疗的获益与危害
该纵向队列研究从临床实践研究数据链提取1998年1月1日至2015年9月30日数据,纳入18至74岁、未经治疗血压140/90-159/99 mm Hg且无心血管病或危险因素的低危轻度高血压患者。采用倾向评分匹配,19143例治疗患者与19143例未治疗患者配对。中位随访5.8年,治疗与死亡率(HR 1.02;95%CI 0.88-1.17)及心血管病(HR 1.09;95%CI 0.95-1.25)无显著关联,但低血压、晕厥、电解质异常和急性肾损伤风险增加。作者认为该预设分析不支持指南鼓励对此类患者启动治疗的建议,提示医生遵循将高危人群试验结果推广至低危人群的指南时应谨慎。
要点
- 低危轻度高血压(140/90-159/99 mm Hg)患者启动降压治疗与死亡率无显著关联(HR 1.02;95%CI 0.88-1.17)。
- 治疗与心血管病风险无显著关联(HR 1.09;95%CI 0.95-1.25)。
- 治疗与低血压风险增加相关(HR 1.69;95%CI 1.30-2.20;10年需伤害人数41)。
- 治疗与晕厥风险增加相关(HR 1.28;95%CI 1.10-1.50;10年需伤害人数35)。
- 治疗与电解质异常(HR 1.72;95%CI 1.12-2.65;10年需伤害人数111)和急性肾损伤(HR 1.37;95%CI 1.00-1.88;10年需伤害人数91)风险增加相关。
适用人群与场景
- 18至74岁、未经治疗血压140/90-159/99 mm Hg的轻度高血压患者。
- 排除有心血管病史或心血管病危险因素的患者。
诊断标准与关键阈值
- 轻度高血压定义为未经治疗血压140/90-159/99 mm Hg。
- 低危定义为无心血管病史且无心血管病危险因素。
研究设计与关键结果
- 纵向队列研究,从临床实践研究数据链提取1998年1月1日至2015年9月30日数据,19143例治疗患者与19143例未治疗患者经倾向评分匹配。
- 中位随访5.8年(四分位距2.6-9.0年),治疗与死亡率无显著关联(HR 1.02;95%CI 0.88-1.17),与心血管病无显著关联(HR 1.09;95%CI 0.95-1.25)。
- 治疗与低血压风险增加相关(HR 1.69;95%CI 1.30-2.20;10年需伤害人数41),与晕厥风险增加相关(HR 1.28;95%CI 1.10-1.50;10年需伤害人数35)。
- 治疗与电解质异常风险增加相关(HR 1.72;95%CI 1.12-2.65;10年需伤害人数111),与急性肾损伤风险增加相关(HR 1.37;95%CI 1.00-1.88;10年需伤害人数91)。
证据类型、等级与局限
- 证据类型:纵向队列研究。
- 作者结论:该预设分析未发现证据支持指南鼓励对低危轻度高血压患者启动治疗的建议;不良事件风险增加提示医生在遵循将高危人群试验结果推广至低危人群的指南时应谨慎。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于低危轻度高血压患者,启动降压治疗与死亡率及心血管病无显著关联,但低血压、晕厥、电解质异常和急性肾损伤风险增加。
- 作者认为,医生在遵循将高危人群试验结果推广至低危人群的指南时应谨慎。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Evidence to support initiation of pharmacologic treatment in low-risk patients with mild hypertension is inconclusive, with previous trials underpowered to demonstrate benefit. Clinical guidelines across the world are contradictory.
OBJECTIVE: To examine whether antihypertensive treatment is associated with a low risk of mortality and cardiovascular disease (CVD) in low-risk patients with mild hypertension.
DESIGN, SETTING, AND PARTICIPANTS: In this longitudinal cohort study, data were extracted from the Clinical Practice Research Datalink, from January 1, 1998, through September 30, 2015, for patients aged 18 to 74 years who had mild hypertension (untreated blood pressure of 140/90-159/99 mm Hg) and no previous treatment. Anyone with a history of CVD or CVD risk factors was excluded. Patients exited the cohort if follow-up records became unavailable or they experienced an outcome of interest.
EXPOSURES: Prescription of antihypertensive medication. Propensity scores for likelihood of treatment were constructed using a logistic regression model. Individuals treated within 12 months of diagnosis were matched to untreated patients by propensity score using the nearest-neighbor method.
MAIN OUTCOMES AND MEASURES: The rates of mortality, CVD, and adverse events among patients prescribed antihypertensive treatment at baseline, compared with those who were not prescribed such treatment, using Cox proportional hazards regression.
RESULTS: A total of 19 143 treated patients (mean [SD] age, 54.7 [11.8] years; 10 705 [55.9%] women; 10 629 [55.5%] white) were matched to 19 143 similar untreated patients (mean [SD] age, 54.9 [12.2] years; 10 631 [55.5%] female; 10 654 [55.7%] white). During a median follow-up period of 5.8 years (interquartile range, 2.6-9.0 years), no evidence of an association was found between antihypertensive treatment and mortality (hazard ratio [HR], 1.02; 95% CI, 0.88-1.17) or between antihypertensive treatment and CVD (HR, 1.09; 95% CI, 0.95-1.25). Treatment was associated with an increased risk of adverse events, including hypotension (HR, 1.69; 95% CI, 1.30-2.20; number needed to harm at 10 years [NNH10], 41), syncope (HR, 1.28; 95% CI, 1.10-1.50; NNH10, 35), electrolyte abnormalities (HR, 1.72; 95% CI, 1.12-2.65; NNH10, 111), and acute kidney injury (HR, 1.37; 95% CI, 1.00-1.88; NNH10, 91).
CONCLUSIONS AND RELEVANCE: This prespecified analysis found no evidence to support guideline recommendations that encourage initiation of treatment in patients with low-risk mild hypertension. There was evidence of an increased risk of adverse events, which suggests that physicians should exercise caution when following guidelines that generalize findings from trials conducted in high-risk individuals to those at lower risk.
参考来源
- Sheppard JP, Stevens S, Stevens R, et al. Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension. JAMA Intern Med. 2018. PMID: 30383082. doi:10.1001/jamainternmed.2018.4684
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。